Jemperli, illustration of tablet bottle form (not a photo of the actual pack)

Illustrative image.

Jemperli

Dostarlimab

Prescription required

$10890.00

500mg · 1 bottle

BrandBranded medicine· By GlaxoSmithKline

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

About Jemperli

Overview

Jemperli (dostarlimab) is an antibody medicine used with carboplatin and paclitaxel, then continued alone, to treat adults with endometrial cancer that is advanced at diagnosis or has returned. It is also used alone for recurrent or advanced endometrial cancer confirmed by an FDA-approved test to be mismatch repair deficient (dMMR), after progression during or after platinum-containing treatment, when curative surgery or radiation is not an option. Jemperli can also treat adults with other recurrent or advanced dMMR solid tumors confirmed by an FDA-approved test, after progression during or after prior treatment and when no satisfactory alternatives remain; this use has accelerated approval, with continued approval potentially dependent on confirmatory trials verifying clinical benefit. It works by blocking PD-1, helping release a brake on the immune system’s response against tumors.

What it treats

• Primary advanced or recurrent endometrial cancer in adults, used with carboplatin and paclitaxel, then continued alone. • Recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer in adults, confirmed by an FDA-approved test, that has progressed during or after platinum-containing treatment, when curative surgery or radiation is not an option. Used alone. • Recurrent or advanced dMMR solid tumors in adults, confirmed by an FDA-approved test, that have progressed during or after prior treatment, with no satisfactory alternative treatment options. Used alone. This indication has accelerated approval based on tumor response and how long it lasts; continued approval may depend on confirmation of clinical benefit.

Safety information

Side effects

Common side effects of Jemperli (dostarlimab) used alone in patients with mismatch repair-deficient (dMMR) solid tumors include tiredness or weakness, anemia, diarrhea and nausea. When used with carboplatin and paclitaxel in patients with endometrial cancer, common side effects include tiredness, nausea, vomiting, hair loss, nerve problems in the hands or feet, joint pain, rash, constipation, diarrhea, abdominal pain, shortness of breath, reduced appetite and urinary tract infections. Common blood test changes include reduced blood cell counts, increased blood sugar, changes in liver and kidney tests, and reduced levels of certain minerals and albumin, a blood protein. With Jemperli used alone, severe laboratory abnormalities can include low lymphocyte counts, low sodium, increased alkaline phosphatase and low albumin. Contact your doctor promptly about suspected serious side effects. Jemperli can cause immune-related reactions in any organ or tissue. These may be severe or fatal and include inflammation of the lungs, bowel, liver or kidneys, hormone gland disorders, serious skin reactions and rejection of a transplanted organ. Blood tests to check liver, kidney and thyroid function are needed before and during treatment. Reactions can also occur during the infusion. Tell the treatment team immediately if you develop a reaction. Serious or fatal complications can occur in people who receive a donor stem cell transplant before or after treatment. Jemperli can harm an unborn baby. Use effective contraception if you could become pregnant, and contact your doctor if pregnancy occurs.

When to call your doctor

• Seek medical attention immediately for shortness of breath. • Seek medical attention immediately for severe diarrhea or severe abdominal pain. • Seek medical attention immediately for a severe rash.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The FDA label lists no contraindications for Jemperli (dostarlimab). However, important warnings apply: Jemperli can cause severe or fatal immune reactions affecting any organ or tissue, including the lungs, bowel, liver, hormone-producing glands, kidneys and skin. It can also cause rejection of a transplanted organ. Monitoring includes liver enzymes, kidney function and thyroid function before and during treatment. Depending on severity, treatment may need to be paused or permanently stopped, and corticosteroids may be needed. Infusion-related reactions can occur and may require the infusion to be slowed, interrupted or permanently stopped. Serious or fatal complications can occur in people who receive a stem cell transplant from a donor before or after treatment. Jemperli can harm an unborn baby. People who could become pregnant should use effective contraception. Do not breastfeed during treatment.

Using Jemperli

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place with the bottle tightly closed, away from direct light and moisture. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label JEMPERLI (DOSTARLIMAB) INJECTION [GLAXOSMITHKLINE LLC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines